Condition
BCR-ABL Positive Acute Lymphoblastic Leukemia
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Withdrawn1
Not Yet Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07301424Phase 2Not Yet Recruiting
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
NCT03515785WithdrawnPrimary
A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"
Showing all 2 trials